189 related articles for article (PubMed ID: 38540310)
1. Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines.
Irie N; Mizoguchi K; Warita T; Nakano M; Sasaki K; Tashiro J; Osaki T; Ishikawa T; Oltvai ZN; Warita K
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540310
[TBL] [Abstract][Full Text] [Related]
2. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
[TBL] [Abstract][Full Text] [Related]
3. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
[TBL] [Abstract][Full Text] [Related]
4. HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.
Zhou Y; Tashiro J; Kamatani S; Irie N; Suzuki A; Ishikawa T; Warita K; Oltvai ZN; Warita T
Biochem Biophys Res Commun; 2023 Oct; 677():13-19. PubMed ID: 37541087
[TBL] [Abstract][Full Text] [Related]
5. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
6. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.
Pandyra A; Mullen PJ; Kalkat M; Yu R; Pong JT; Li Z; Trudel S; Lang KS; Minden MD; Schimmer AD; Penn LZ
Cancer Res; 2014 Sep; 74(17):4772-82. PubMed ID: 24994712
[TBL] [Abstract][Full Text] [Related]
7. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Longo J; Pandyra AA; Stachura P; Minden MD; Schimmer AD; Penn LZ
Mol Oncol; 2020 Oct; 14(10):2533-2545. PubMed ID: 32749766
[TBL] [Abstract][Full Text] [Related]
8. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
Pandyra AA; Mullen PJ; Goard CA; Ericson E; Sharma P; Kalkat M; Yu R; Pong JT; Brown KR; Hart T; Gebbia M; Lang KS; Giaever G; Nislow C; Moffat J; Penn LZ
Oncotarget; 2015 Sep; 6(29):26909-21. PubMed ID: 26353928
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells.
Ishikawa T; Osaki T; Sugiura A; Tashiro J; Warita T; Hosaka YZ; Warita K
Vet Comp Oncol; 2022 Mar; 20(1):313-323. PubMed ID: 34657361
[TBL] [Abstract][Full Text] [Related]
11. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
[TBL] [Abstract][Full Text] [Related]
12. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
Carroll MJ; Parent CR; Page D; Kreeger PK
BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
[TBL] [Abstract][Full Text] [Related]
14. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the anticancer effects of various statins on canine oral melanoma cells.
Ishikawa T; Irie N; Tashiro J; Osaki T; Warita T; Warita K; Naito M
Vet Comp Oncol; 2024 Mar; 22(1):156-161. PubMed ID: 38044042
[TBL] [Abstract][Full Text] [Related]
16. Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins.
van Leeuwen JE; Ba-Alawi W; Branchard E; Cruickshank J; Schormann W; Longo J; Silvester J; Gross PL; Andrews DW; Cescon DW; Haibe-Kains B; Penn LZ; Gendoo DMA
Nat Commun; 2022 Oct; 13(1):6323. PubMed ID: 36280687
[TBL] [Abstract][Full Text] [Related]
17. Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.
Ishikawa T; Hosaka YZ; Beckwitt C; Wells A; Oltvai ZN; Warita K
Oncotarget; 2018 Jun; 9(50):29304-29315. PubMed ID: 30034619
[TBL] [Abstract][Full Text] [Related]
18. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S
Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968
[TBL] [Abstract][Full Text] [Related]
19. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one.
Pandyra A; Penn LZ
Mol Cell Oncol; 2014; 1(4):e969133. PubMed ID: 27308369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
